Drug interactions
Encorafenib + Linagliptin-metformin
Severity: Minor
Encorafenib and Linagliptin-metformin: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib can both inhibit and induce CYP3A4, so linagliptin exposure could rise or fall. The effect on linagliptin is uncertain, and its wide therapeutic margin limits clinical concern.
What this interaction means in plain words
Encorafenib and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Encorafenib belongs to Oncology; Linagliptin-metformin belongs to Endocrine.
Why it happens
Mixed CYP3A4 inhibition and induction by encorafenib alters linagliptin metabolism unpredictably.
What to do
Monitor glycemic control during encorafenib therapy and adjust antidiabetic treatment if response changes.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Linagliptin-metformin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Linagliptin-metformin?
MediHelp rates the interaction as minor. Encorafenib and Linagliptin-metformin have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Encorafenib can both inhibit and induce CYP3A4, so linagliptin exposure could rise or fall. The effect on linagliptin is uncertain, and its wide therapeutic margin limits clinical concern.
How serious is the interaction between Encorafenib and Linagliptin-metformin?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor glycemic control during encorafenib therapy and adjust antidiabetic treatment if response changes.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
